Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Adults 18-80 years of age

• Starting semaglutide for type 2 diabetes or weight loss

• Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Locations
Other Locations
Canada
Mazankowski Alberta Heart Institute
RECRUITING
Edmonton
Contact Information
Primary
Krista Jong, RD, BSc
glimmer@ualberta.ca
780-492-9010
Time Frame
Start Date: 2026-04-14
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: University of Alberta

This content was sourced from clinicaltrials.gov